Antiarrhythmic drug efficacy for @entity1165 associated with XXXX as assessed by electrophysiologic studies.

@entity1 @entity1165 @entity943 @entity2683 @entity591 @entity5126 @entity2224 @entity453 @entity1818
The efficacy and proarrhythmic potential of antiarrhythmic agents were evaluated. Programmed ventricular stimulation was performed in 160 consecutive @entity1 with @entity453 during a baseline study and 432 subsequent drug studies. The @entity591 induced during baseline studies were sustained @entity1165 (121 @entity1 ), @entity2224 (16 @entity1 ), and symptomatic nonsustained @entity1165 (23 @entity1 ). Regimens were completely successful if fewer than 6 repetitive ventricular responses were inducible during therapy and partially successful if no more than 15 repetitive ventricular responses were inducible. @entity1818 and @entity5126 were the most successful single agents, with overall success rates of 24% and 35%, respectively. Either @entity1818 or @entity5126 combined with @entity2683 was the most successful combination (overall success of 23%). Each anti-arrhythmic regimen showed a proarrhythmic potential. The incidence of proarrhythmic effects ranged from 4 to 13%, with no significant difference between regimens. In 13% of @entity1 at least 1 regimen produced a proarrhythmic effect. @entity1 treated with an antiarrhythmic regimen that prevented induction of @entity943 had significantly fewer @entity943 recurrences than @entity1 treated with a regimen that failed to prevent it. In conclusion, identification of an effective drug regimen is possible in 38% of @entity1 with lethal @entity943 , proarrhythmic effects occur in a significant number of @entity1 during electrophysiologic testing of antiarrhythmic regimens, and the clinical outcome in @entity1 in whom @entity943 are not inducible with ventricular stimulation have a better prognosis than those in whom @entity943 continue to be inducible on therapy.
